Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Spotify Technology — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Spotify Technology trades at $501.08 (market cap $105.22B). The key difference: Spotify Technology is far larger — about 11.2× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| BIO | SPOT | |
|---|---|---|
Market Cap | $9.39B | $105.22B |
Sector | Health | Media |
52-Week High | $356.25 | $738.53 |
52-Week Low | $241.71 | $412.75 |
Enterprise Value | $9.14B | $94.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Spotify (SPOT) trades at $488.14, up 2.75% with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with Q2 2026 revenue growth of 14% year-over-year and record gross margins of 33.4%, though earnings missed expectations due to increased marketing and AI costs. Premium subscribers surpassed 300 million for the first time, supporting the long-term growth narrative.
Wall Street maintains a bullish outlook with 61.5% buy ratings and a $598.20 consensus price target representing 22.5% upside potential. Key risks include execution on AI investments, competitive pressure in streaming, and margin sustainability. The stock presents growth opportunity if monetization initiatives succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
